A comparison of thrombotic thrombocytopenic purpura in an inception cohort of patients with and without systemic lupus erythematosus

Rheumatology

Volumn 48, Issue 4, 2009, Pages 399-403

  Letchumanan, Pagalavan ^a   Ng, Heng Joo ^b   Lee, Lai Heng ^b   Thumboo, Julian ^b,c  

^a MONASH UNIVERSITY MALAYSIA   (Malaysia)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c Dept Medicine Endocrinol Diabet   (Singapore)

Author keywords

Autoantibodies; Biological therapies; Immunosuppressants; Plasmapheresis; Rituximab; SLE; Thrombotic thrombocytopenic purpura

Indexed keywords

ANTINUCLEAR ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HYDROCORTISONE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE DURATION; DRUG CHOICE; DRUG MEGADOSE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MALE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PLASMAPHERESIS; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PLASMAPHERESIS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SINGAPORE; VINCRISTINE;

EID: 63249095240     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken510     Document Type: Article

References (30)

1. Moschowitz E, Hyaline thrombosis of terminal arterioles and capillaries: a hitherto underscribed disease. Proc NY Pathol Soc 1924;24:21-4.
2. Rock GA, Shumak KH, Buskard NA et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991;325:393-7.
3. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002;347:589-600.
4. Terrell DR, Williams LA, Vesely SK, Lammle B, Hovinga JA, George JN. The incidence of thrombotic thrombocytopenic purpura - hemolytic uremic syndrome: All patients, idiopathic patients and patients with severe ADAMTS-13 deficiency. J Thromb Haemost 2005;3:1432-6.
5. Byrnes JJ, Moake JL. Thrombotic thrombocytopenic purpura and the hemolytic-uraemic syndrome: Evolving concepts of pathogenesis and therapy. Clin Haematol 1986;15:413-42.
6. Remuzzi G. HUS and TTP: Variable expression of a single entity. Kidney Int 1987; 32:292-308.
7. Ruggenenti P, Remuzzi G. Thrombotic thrombocytopenic purpura and related disorders. Haematol Oncol Clin North Am 1990;4:219-41.
8. Asherson RA, Cervera R. Microvascular and microangopathic antiphospholipid-associated syndromes (MAPS): Sematic or antisematic? Autoimmunity Rev 2008;7: 164-7.
9. Devinski O, Petito CK, Alonso DR. Clinical and neuropathological findings in systemic lupus erythematosus: The role of vasculitis, heart emboli and thrombotic thrombocytopenic purpura. Ann Neurol 1988;23:380-4.
10. Allford SL, Hunt BJ, Rose P, Machin SJ. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 2003;120:556-73.
11. Aamer A, Saleh AS. Thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus. Acta Haem 2006;115:68-73.
12. Nesher G, Hanna VE, Moore TL, Hersh M, Osborn TG. Thrombotic microangiopathic hemolytic anaemia in systemic lupus erythematosus. Semin Arthritis Rheum 1994, 24:165-72.
13. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
14. George JN. Clinical practise. Thrombotic thrombocytopenic purpura. N Engl J Med 2006;354:1927-35.
15. Kremer E, Hovinga JA, Studt JD, Lammle B. The von Willebrand factor-cleaving protease (ADAMTS-13) and the diagnosis of thrombotic thrombocytopenic purpura (TTP). Pathophysiol Haemost Thromb 2004;33:417-21.
16. Furlan M, Robles R, Galbusera M et al. Von Willebrand factor cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. N Engl J Med 1998;339:1578-84.
17. Peyvandi F, Ferrari S, Lavoretano S, Canciani MT, Mannucci PM. Von Willebrand factor cleaving protease (ADAMTS-13) and ADAMST-13 neutralizing autoantibodies in 100 patients with thromotic thrombocytopenic purpura. Br J Haematol 2004;127: 433-9.
18. Tsai HM, Chun YL. Antibodies to von Willebrand factor cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585-94.
19. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific von Willebrand factor cleaving protease in thrombotic microangiopathies: A study of 111 cases. Blood 2001;98:1765-72.
20. Fessler BJ. Thrombotic syndromes and autoimmune diseases. Rheum Dis Clin North Am 1997;23:461-79.
21. Coppo P, Bengoufa D, Veyradier A et al. Severe ADAMTS-13 deficiency in adult idopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count and mild renal involvement. Medicine 2004;83:233-44.
22. Musio F, Bohen EM, Yuan CM, Welch PG. Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus. Semin Arthritis Rheum 1998; 28:1-19.
23. Hamasaki K, Mimura T, Kanda H et al. Systemic lupus arythematosus and thrombotic thrombocytopenic purpura: A case report and literature review. Clin Rheumatol 2003;22:355-8.
24. Dervenoulas J, Tsirigotis P, Bollas G et al. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS): Treatment outcome, relapses, prognostic factor. A single center experience of 48 cases. Ann Hematol 2000;79:66-72.
25. Vasoo S, Thumboo J, Fong KY. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: Disease activity and the use of cytotoxic drugs. Lupus 2002; 11:443-50.
26. Pereira A, Mazzara R, Monteagudo J et al. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: A multivariate analysis of factors predicting the response to plasma exchange. Ann Hematol 1995;70:319-23.
27. Halim AG, Soehardy Z, Shahrir MS et al. Rituximab in recalcitrant thrombotic thrombocytopenic purpura secondary to systemic lupus erythematosus. Int J Rheum Dis 2008;11:69-72.
28. Arnold DM, Francesco D, Crowther MA et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007;146:25-33.
29. Scully M, Cohen H, Cavenagh J et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMST-13. Br J Haematol 2007;136:451-61.
30. George JN, Woodson RD, Kiss JE, Kojouri K, Vesely SK. Rituximab therapy for thrombotic thrombocytopenic purpura: A proposed study of the transfusion medicine/hemostasis clinical trials network with a systemic review of rituximab therapy for immune mediated disease. J Clin Apher 2006;21:49-56.